Article Text
Editorial
Riociguat for pulmonary hypertension in congenital heart disease: opportunities and challenges
Statistics from Altmetric.com
Footnotes
Contributors Both authors contributed to the writing and critical review of the manuscript.
Competing interests AEL and G-PD have received grants from Actelion and Pfizer, UK and Global.
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Pulmonary vascular disease
- Heartbeat